AACR 2023: A Novel Triple Humanized B-hPD-1/hPD-L1/hCCR8 Mouse Model to Evaluate In vivo Efficacy of Combination Therapies
Used in the poster: B-hPD-1/hPD-L1/hCCR8 mice
- Protein expression analysis:
Human PD-1, PD-L1 and CCR8 proteins were detected in homozygous B-hPD-1/hPD-L1/hCCR8 mice, but not in wild-type mice.
- In vivo efficacy of anti-human PD-1 and CCR8 antibodies:
Anti-human PD-1 antibody combined with an anti-human CCR8 antibody controlled B-hPD-L1 MC38 plus tumor growth in B-hPD-1/hPD-L1/hCCR8 mice.